Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort.
Lydia C T BuerBjørn A MoumMilada CvancarovaDavid J WarrenNils BolstadAsle W MedhusMarte L HøivikPublished in: Scandinavian journal of gastroenterology (2019)
Improvement of biochemical markers of inflammation was observed in CD while clinical activity scores improved in UC patients. For CD, baseline CRP was correlated with lower concentrations of p-VDZ at week 14.
Keyphrases
- patients with inflammatory bowel disease
- end stage renal disease
- newly diagnosed
- ejection fraction
- randomized controlled trial
- chronic kidney disease
- systematic review
- peritoneal dialysis
- prognostic factors
- electronic health record
- nk cells
- ulcerative colitis
- machine learning
- patient reported outcomes
- study protocol